Introduction {#section1-1559325815590395}
============

Metabolic disorders remain the leading causes of morbidity and mortality in the modern world. Type 2 diabetes mellitus (T2DM), obesity, and associated cardiovascular diseases are on the rise which makes them one of the most important public health challenges.

According to the World Health Organization ([@bibr89-1559325815590395]), worldwide obesity has nearly doubled since 1980. In 2008, more than 1.4 billion adults were overweight, and of these 200 million men and approximately 300 million women were obese. In 2012, more than 40 million children under the age of 5 were overweight or obese.

In a similar manner, the global prevalence of diabetes is rapidly increasing with an estimated number of 285 million cases of diabetes worldwide, 90% of whom have T2DM. According to the predictions, this number will rise to 439 million by 2030 ([@bibr22-1559325815590395]).

The connection between both diseases is firmly established with obesity as one of the single more important risk factors for the development of T2DM. Epidemiological studies show that 60% to 90% of all patients with T2DM are or have been obese ([@bibr32-1559325815590395]; [@bibr77-1559325815590395]). Nevertheless, the problem is even more complex, and there is also a high incidence of T2DM in normal weight individuals. This is the case of Asian population with one of the highest prevalence of T2DM in a population with the lowest body mass index ([@bibr90-1559325815590395]). This phenomenon came to coin the term of "metabolically obese" which revealed that the key factor in the development of this pathology is the appearance of insulin resistance independent of overweight ([@bibr22-1559325815590395]).

In the etiology of these disorders, there is a strong genetic component; however, their rapidly increasing incidence seems difficult to explain just as a result of genetic changes, which comes to emphasize the important contribution of the environmental factors ([@bibr60-1559325815590395]; [@bibr55-1559325815590395]). Of note, novel environmental factors such as endocrine disrupting chemicals (EDCs) are emerging as key players. The EDCs are defined as "an exogenous chemical, or mixture of chemicals, that interferes with any aspect of hormone action and consequently causes adverse health effects in an intact organism, or its progeny" ([@bibr23-1559325815590395]). According to a more recent definition reported by an Endocrine Society Statement, "An endocrine disrupting chemical (EDC) is an exogenous chemical, or mixture of chemicals, that can interfere with any aspect of hormone action" ([@bibr91-1559325815590395]). Studies in animal models as well as human epidemiological studies have shown that some EDCs can have a diabesogenic behavior ([@bibr4-1559325815590395]; [@bibr19-1559325815590395]; [@bibr34-1559325815590395]).

In addition to that, increasing evidence supports the theory commonly named "developmental or fetal origins of adult disease," which states that adverse influences early in the development and particularly during intrauterine life are related to subsequent physiological disturbances in adulthood, resulting in an increased risk of developing chronic disease in adult life ([@bibr10-1559325815590395]). This paradigm establishes a relationship between a nonoptimal gestational environment and an increased propensity to develop adult-onset metabolic disease.

Strong support for this idea comes from studies that show a positive correlation between low birth weight and increased risk of cardiovascular disease, hypertension, and T2DM ([@bibr29-1559325815590395]). High birth weight or an excessive gestational weight gain has been shown to predispose to higher obesity risk later in life ([@bibr57-1559325815590395]; [@bibr20-1559325815590395]).

The underlying causal mechanisms still remain unknown, but altered maternal--fetal nutrition and increased glucocorticoid exposure have been proposed to be decisive ([@bibr87-1559325815590395]). In addition, the exposure to environmental hazards during critical periods of development has recently been highlighted as an important contributor. Increased incidence of breast cancer ([@bibr50-1559325815590395]), genital tract abnormalities ([@bibr73-1559325815590395]), and fertility problems ([@bibr71-1559325815590395]) are some of the most common abnormalities associated with early EDCs exposure. In addition, prenatal treatment with bisphenol-A (BPA) has been related to the development of obesity and diabetes ([@bibr35-1559325815590395]; [@bibr52-1559325815590395]; [@bibr7-1559325815590395]). In this review, we will analyze the experimental and epidemiological findings that point to BPA as an important risk factor in the adult origin of metabolic diseases.

Bisphenol-A {#section2-1559325815590395}
===========

Bisphenol-A was first synthesized by Dianin in 1891 and then reported to be a synthetic estrogen in the 1930s ([@bibr25-1559325815590395]). In the 1950s, BPA was introduced in the plastic industry and used as the base compound in the manufacture of polycarbonate plastic and the resin lining of food and beverage cans. It is also used as an additive in other widely used plastics such as polyvinyl chloride and polyethylene terephthalate. Numerous studies have found that BPA can leach from polycarbonate containers. Heat and either acidic or basic conditions accelerate the hydrolysis of the ester bond linking BPA monomers, leading to a release of BPA with the concomitant potential human exposure ([@bibr39-1559325815590395]; [@bibr61-1559325815590395]). BPA has been detected in 93% of urine samples in the United States ([@bibr17-1559325815590395]). It has been found to be present in amniotic fluid, neonatal blood, placenta, cord blood, and human breast milk ([@bibr61-1559325815590395]). Its concentration in human serum ranges from 0.2 to 1.6 ng/mL (0.88-7.0 nmol/L; [@bibr66-1559325815590395]; [@bibr79-1559325815590395]).

According to the Environmental Protection Agency (EPA), the lowest adverse effect level for BPA was established at 50 mg/kg/d. Based on that, the reference dose, which is considered an estimate of a daily exposure to the human population that is supposed to be without an appreciable risk of deleterious effects during a lifetime, is 50 µg/kg/d ([@bibr27-1559325815590395])

In 2006, the European Food and Safety Authority (EFSA) set the tolerable daily intake (TDI) as 50 µg/kg/d. In 2013, the authority again evaluated this level of exposure. In January 2014, EFSA identified likely adverse effects on liver and kidney as well as on the mammary gland as being linked to exposure to this chemical. As a result they recommended that the current TDI to be lowered from its current level of 50 µg/kg bw/d to 5 µg/kg bw/d ([@bibr26-1559325815590395]).

There are already hundreds of in vivo studies concerning low-dose effects of BPA published in peer-reviewed journals. A large number of them have demonstrated deleterious effects below the established reference dose. These effects include among others alteration of mammary gland development, behavioral effects, abnormalities in the prostate growth, alterations of sexual maturation, altered immune system function, detrimental effects on glucose homeostasis and insulin sensitivity, and so on ([@bibr83-1559325815590395]; [@bibr61-1559325815590395]).

Experimental Evidence for the Obesogenic Behavior of BPA {#section3-1559325815590395}
========================================================

In the last decade, experimental research conducted in animals has shown that the exposure to BPA, as well as others EDCs, during critical developmental stages can influence lipid and energy balance promoting adipogenesis. Based on that, it has been predicted that environmental pollutants can contribute to the epidemic of obesity ([@bibr31-1559325815590395]; [@bibr36-1559325815590395]).

In 1999, Howdeshell and collaborators demonstrated that the treatment of pregnant CF-1 mice fed with BPA at a dose of 2.4 µg/kg on days 11 to 17 of gestation provoked an increased body weight on postnatal day 22. Curiously, the effect was dependent on fetus position in such manner that it was higher in those fetuses positioned between 2 female fetuses ([@bibr37-1559325815590395]).

When the administration occurred via drinking water, the effects on adipogenesis have also been reported. Offspring from rats exposed to BPA 0.1 mg/kg or 1.2 mg/kg from day 6 of pregnancy through the period of lactation showed an increase in body weight that resulted evident soon after birth and seemed to continue into adulthood ([@bibr64-1559325815590395]). Also, the BPA exposure from day 10 of gestation throughout the lactation period, but at lower doses (1 µg/mL or 10 µg/mL), resulted in an increment of adipose tissue and body weight ([@bibr49-1559325815590395]). Changes in the expression of some important adipogenic genes including PPAR-γ (peroxisome proliferator activated receptor gamma), SREBP-1C (sterol regulatory element binding protein-1C), SCD-1 (stearoyl-CoA desaturase 1) and C/EBP-α (CCAAT/enhancer-binding protein alpha) have been also observed in female offspring at 21 days of age after perinatal exposure to 1 mg/L BPA ([@bibr74-1559325815590395]). Shorter subcutaneous exposures to BPA (0.5 or 10 mg/kg) in pregnant CD-1 mice also result in an accelerated body weight gain in female offspring ([@bibr53-1559325815590395]). Interestingly, the effects of BPA exposure during pregnancy are restricted not only to changes in body weight but also to other characteristic symptoms that encompass the metabolic syndrome. One of the major studies that address this problem was conducted by Angle and collaborators in 2013 ([@bibr9-1559325815590395]). The authors showed in an elegant manner that the administration of BPA in a range from 5 to 50 000 µg/kg/d disrupts energy balance, with maximal responses at doses from 5 to 500 µg/kg/d. In general terms, they observed an increased postnatal body weight; changes in adipocyte number and volume of abdominal fat; and glucose intolerance together with alterations of leptin, insulin, and adiponectin levels in serum when animals reach 19 weeks old ([@bibr9-1559325815590395]). According to this, BPA exposure during gestation and lactation (0-3000 µg/kg/d) led to increased body weight in males after weaning, effect that persisted until adulthood, as well as increased liver weight. Curiously, the effect in females was opposite to that in males, with a dose-dependent decrease in body weight, liver, muscle, adipocyte number, and serum lipids. In addition, females showed increased expression of UCP1 and lipid accumulation in brown adipose tissue ([@bibr82-1559325815590395]). In another study, the perinatal exposure to 50 ng, 50 µg, and 50 mg BPA/kg of diet resulted in an overall increase in energy expenditure in both males and females ([@bibr8-1559325815590395]). Higher doses of BPA via drinking water along with fructose promoted no changes in body weight or volume adipocyte but an increased liver fat content ([@bibr63-1559325815590395]).

When combining BPA exposure with a metabolic stressor, such as a high-fat diet (HFD), there is an exacerbation of the underlying metabolic disorders that accounts for BPA action. This is the case of the study reported by Wei and collaborators, in which pregnant rats were orally exposed to BPA (50, 250, or 1250 µg/kg/d) during both gestation and lactation. Later on, pups were fed with normal diet or HFD. The results showed that under a normal diet, BPA was able to promote glucose intolerance and increased body weight and insulin levels in male offspring, at least under the dose of 50 µg/kg/d. Interestingly, these effects were clearly aggravated by the administration of a HFD which resulted in dyslipidemia, obesity, glucose intolerance, and structural damages in pancreatic β-cells ([@bibr88-1559325815590395]). Subcutaneously, BPA administration (10 µg/kg/d) from day 9 to 16 of gestation has also marked effects in lipid metabolism in male offspring. Remarkably, the body weight of BPA-treated animals reached levels comparable to those animals fed with HFD unexposed to BPA when reaching 20 weeks old. Changes in the messenger RNA expression of genes involved in glucose and lipid metabolism in adipose tissue, liver, and muscle resembled that of HFD-fed animals. Major changes were observed in genes involved in fatty acid metabolism such as SREBPC1, PPARα (peroxisome proliferator activated receptor alpha), and CPT 1β (carnitine palmitoyltransferase 1β). A diminished expression of Cd36 was also observed ([@bibr28-1559325815590395]).

Changes in the hypothalamic energy balance system were also found when combining oral perinatal exposure to BPA (from 0.19 to 7.2 μg/kg/d) with HFD, when reaching adulthood in a sex-dependent manner ([@bibr44-1559325815590395]).

As regards other periods of exposure, it has been shown that the treatment with 50 µg/kg of BPA for 4 days just after birth provoked an increase in body weight that was apparent on postnatal day 68 ([@bibr58-1559325815590395]). In contrast, the effects of BPA on energy balance during adulthood still remain unclear. The administration of BPA to ovariectomized rats at a dose of 4 or 5 mg/d during 15 days has been reported to decrease body weight gain ([@bibr54-1559325815590395]), although treatment with lower doses (8.9 or 88 µg BPA/d for 3 months) showed no effect ([@bibr68-1559325815590395]).

In Vitro Studies and Mechanisms Proposed {#section4-1559325815590395}
----------------------------------------

In vitro experiments also reveal the obesogenic behavior of BPA. Most of the studies leading to that conclusion have been performed in the adipocyte cell line 3T3-L1 or in human adipose stromal/stem cells. Masuno and collaborators demonstrated that the treatment of 3T3-L1 cells in the presence of BPA in the range dose of µmol/L promoted an increase in triglyceride content and adipogenesis ([@bibr47-1559325815590395]; [@bibr46-1559325815590395]). This phenomenon was later confirmed in the same cell line at a concentration of 10 to 100 nmol/L, although no induction of adipogenesis was observed in mesenchymal stromal stem cells ([@bibr21-1559325815590395]). Other studies observed BPA-mediated adipogenic differentiation processes in human adipose stromal/stem cells ([@bibr56-1559325815590395]). Interestingly, environmental relevant doses of BPA (from 0.1 to 1 nmol/L) have been shown to inhibit adiponectin release and increase the release of interleukin 6 and tumor necrosis factor α in human explants which has special relevance since adiponectin has been reported to be a protective factor for metabolic syndrome ([@bibr38-1559325815590395]; [@bibr12-1559325815590395]).

The adipogenic effect of BPA has been proposed to be mediated by an estrogen receptor (ER)-dependent mechanism with enhanced expression of DLK (leucine zipper-bearing kinase), IGF-1 (insulin-like growth factor-1), C/EBPα, or PPARγ among other factors ([@bibr56-1559325815590395]; [@bibr62-1559325815590395]). In adipose tissue samples from children, it has been reported that BPA promotes adipogenesis by increasing expression of 11β-hydroxysteroid dehydrogenase type 1 and enzyme activity ([@bibr85-1559325815590395]). Recent studies also suggest the implication of the thyroid receptor/retinoic X receptor or mammalian target of rapamycin signaling pathways ([@bibr15-1559325815590395]).

In addition to that, BPA has been proposed to increased triglyceride content and lipid accumulation in a hepatoma cell line associated with a decreased expression of some genes involved in lipid oxidation ([@bibr30-1559325815590395]).

Epidemiological Evidence for the Obesogenic Behavior of BPA {#section5-1559325815590395}
===========================================================

Several epidemiological studies have established a link between BPA levels and obesity. One of the first cross-sectional studies that addressed this association was based on the pooled data from the 2003/04 and 2005/06 National Health and Nutrition Examination Surveys (NHANES). The authors found in adults that urinary BPA concentration was positively associated with general and central obesity, with a slight higher correlation in men than in women ([@bibr18-1559325815590395]). These results were lately confirmed in another study based on NHANES data in which, additionally, it was reported that the association between BPA and obesity was independent of other factors such as age, education, smoking, physical activity, or alcohol intake among others ([@bibr70-1559325815590395]). This positive association was also found in a small sample of Chinese ([@bibr86-1559325815590395]) and Korean adults ([@bibr40-1559325815590395]) as well as in a subpopulation of American women ([@bibr75-1559325815590395]).

An even more worrying fact is that, this phenomenon has been observed not only in adults but also in children and adolescents. A representative cross-sectional study using the data from 2003 to 2008 NHANES evaluated the levels of urinary BPA in participants aged 6 through 19 years and found that the rates of obesity were increased in the second, third, and fourth quartiles of urinary BPA concentration ([@bibr80-1559325815590395]). In subsequent analysis, a strongest positive correlation was observed in boys and in non-Hispanic white children ([@bibr14-1559325815590395]). In a Chinese children population study, BPA was found in 84.9% of urine samples, with an estimated mean of 0.45 ng/mL. Linear regression analysis showed that increasing BPA concentrations were related to higher body mass index values ([@bibr84-1559325815590395]). Curiously, in a Shanghai population, BPA concentration was associated with obesity in female children from 9 to 12 years old but not in male ([@bibr42-1559325815590395]).

New epidemiological studies are being published, in which prenatal exposure to BPA and later outcomes in adiposity are discussed. The first one was performed in a Mexican American population and published in 2013. The authors reported different effects depending on the prenatal or postnatal period. Thus, BPA levels in urine was correlated with a decrease in adiposity in girls at the age of 9 but not in boys, while in accordance with the previous findings, higher levels of urinary BPA were correlated with increased odds of obesity in both girls and boys at the age of 9 ([@bibr33-1559325815590395]). Similar findings as regards early-life BPA exposure have been reported in more recent studies ([@bibr16-1559325815590395]).

Experimental Evidence for the Diabetogenic Behavior of BPA {#section6-1559325815590395}
==========================================================

Prenatal exposure to BPA in different animal models has been shown to result in a wide range of effects in glucose metabolism observed during postnatal life. Offspring of mice exposed to BPA injections 10 µg/kg/d during days 9 to 16 of pregnancy displayed glucose intolerance, insulin resistance, hyperinsulinemia, and altered insulin release from pancreatic β-cells compared to control mice when reaching 6 months of age. Exposure of mice to a higher dose of BPA (100 µg/kg/d) during days 9 to 16 of pregnancy produced a different phenotype in the male offspring at 6 months of age, characterized by glucose intolerance but normal insulin sensitivity and a mild alteration in β-cell function ([@bibr7-1559325815590395]). When pregnant mice were fed with BPA at doses from 5 to 50 000 µg/kg during gestational days 9 to 18, similar effects on glucose tolerance were observed. At the age of 18 weeks, all BPA dose groups, except for the highest one, showed an impairment of glucose tolerance measured as an increased area under the curve for the glucose tolerance test. In addition, at the dose of 5 and 50 µg/kg/d, animals showed decreased insulin sensitivity and higher plasma insulin levels in the first group ([@bibr9-1559325815590395]).

A larger study in regard to periods of exposure to BPA (doses 100 µg/kg/d) was conducted by Liu and collaborators. The authors analyzed different critical windows of exposure including preimplantation, fetal, and neonatal as well as the combination of fetal and neonatal exposure. They found an impairment of glucose tolerance in all periods of exposition in male offspring at the age of 3 months, phenomenon that persisted to 8 months in those males that have been exposed to BPA during the fetal period. Insulin secretion and sensitivity were also reduced with no changes in β-cell mass. The effects were less pronounced in female offspring ([@bibr42-1559325815590395]).

When combining prenatal BPA exposure with later HFD treatment, parameters of glucose and lipid metabolism were severely impaired ([@bibr88-1559325815590395]; [@bibr28-1559325815590395]) as well as decreased pancreatic β-cell function and mass ([@bibr88-1559325815590395]; [@bibr24-1559325815590395]). Interestingly, the administration of BPA (50 µg/kg/d) in rats throughout gestation and lactation was associated with hepatic epigenetic modifications that were proposed to be responsible for the metabolic alterations, insulin resistance, and impaired glucose tolerance, developed in the postnatal life ([@bibr43-1559325815590395]).

Evidence now exists indicating that in adults BPA also provokes adverse metabolic consequences. Experiments performed in male OF-1 mice showed that a single subcutaneous injection of 10 µg/kg of BPA produces a rapid decrease in blood glucose that occurred in parallel to an increase in plasma insulin levels ([@bibr3-1559325815590395]). Prolonged exposure to this compound also have effects on glucose homeostasis. The administration of BPA at a dose 100 µg/kg for a period of 4 days resulted in postprandial hyperinsulinemia, impaired glucose tolerance, and marked insulin resistance ([@bibr3-1559325815590395]). This insulin resistance may be explained by a disruption of insulin signaling in skeletal muscle and liver. The BPA treatment led to decreased phosphorylation of insulin receptor tyrosine , followed by reduced Akt phosphorylation on the residue Thr^308^ in the skeletal muscle. In addition, there is an impairment of insulin-induced ERK (extracelular-signal-regulated kinase) phosphorylation in that tissue. In the liver, the effects were lower with decreased insulin-stimulated tyrosine phosphorylation of the insulin receptor ([@bibr11-1559325815590395]). Longer exposure to BPA in adults impaired hepatic glucokinase activity and function ([@bibr59-1559325815590395]), meanwhile chronic BPA administration during a period of 8 months provoked increased adipose tissue, glucose intolerance, higher levels of cholesterol, and overexpression of key genes involved in cholesterol biosynthesis ([@bibr45-1559325815590395]).

In Vitro Studies and Mechanisms Proposed {#section7-1559325815590395}
----------------------------------------

It is well known that environmental relevant doses of BPA can affect pancreatic α- and β-cell physiology. At a concentration of 1 nmol/L, BPA inhibits calcium oscillations in α-cells, a key event in the glucagon secretion process. This action is characterized by a rapid onset and involves a pertussis toxin-sensitive G-protein, nitric oxide synthase, guanylate cyclase, and PKG (protein kinase G) ([@bibr2-1559325815590395]). As regards β-cells, BPA affects pancreatic β-cell function in 2 different manners in the range doses 100 pmol/L to 10 nmol/L. On one hand, it rapidly provokes the closure of the K~ATP~ channel of β-cells, increasing the frequency of \[Ca^2+^\] oscillations, which finally results in a rapid increased insulin secretion. Genetic and pharmacological tools demonstrated that this effect is mediated by the activation of ERβ out of the nucleus ([@bibr51-1559325815590395]; [@bibr76-1559325815590395]). On the other hand, BPA can affect insulin gene transcription and biosynthesis after binding extranuclear ERα ([@bibr5-1559325815590395]; [@bibr6-1559325815590395]).

Moreover, it has been shown that BPA can affect glucose transport in adipocyte cell models, in a mechanism that includes an increase in the basal and insulin-stimulated glucose transport due to an increased amount of GLUT4 (glucose transporter type 4; [@bibr67-1559325815590395]).

More recently, it has been reported that cultured human adipocytes in the presence of BPA 1 nmol/L showed decreased insulin-stimulated glucose utilization, with no changes in GLUT4 levels. However, an increased basal glucose uptake was observed in this cellular model which was related to increased levels of GLUT1 ([@bibr81-1559325815590395]).

Epidemiological Evidence for the Diabetogen Behavior of BPA {#section8-1559325815590395}
===========================================================

Increasing epidemiological evidence establishes a connection link between BPA levels (predominantly in urine) and incidence of T2DM. The first one was the cross-sectional analysis performed in a representative sample of the adult population of the United States in 2003/2004 (NHANES) which showed that higher urinary levels of BPA were associated with abnormal levels of the liver enzymes γ-glutamyl-transferase, alkaline phosphatase, and lactate dehydrogenase. The authors also established a significant relationship between BPA concentration and T2DM and cardiovascular disease ([@bibr41-1559325815590395]).

A similar study was carried out using later NHANES data from 2005/2006. The authors found that urinary BPA concentrations were significantly lower in 2005/2006 (1.79 ng/mL) than in the population of 2003/2004 (2.49 ng/mL). A correlation between urinary BPA concentrations and an increased prevalence of coronary heart disease was still present. With regard to the prevalence of diabetes and liver enzyme abnormalities, the association with urinary BPA was not significant but the pooled estimate remained significant ([@bibr48-1559325815590395]). Data from 2003/2008 confirmed the association of urinary BPA levels with T2DM in the 2003/04 pool but not in the 2005/06 pool ([@bibr72-1559325815590395]).

Similar studies based on NHANES 2003 to 2008, but taking into consideration fasting glucose levels, as well as glycosylated hemoglobin to define diabetes mellitus, reported a positive association between increasing BPA levels and the incidence of diabetes, which was independent of other factors such as age, gender, or body composition ([@bibr69-1559325815590395]). A positive correlation with prediabetes was also observed ([@bibr65-1559325815590395]). In a representative Chinese adult population, similar findings were observed with a significant relationship between urinary BPA levels and prevalence of insulin resistance ([@bibr86-1559325815590395]). Other studies show the same association between BPA and insulin resistance as well as hyperinsulinemia which was more evident in male than in female ([@bibr13-1559325815590395]). Curiously, a new prospective study established a correlation between BPA concentrations and risk of T2DM in middle-aged but not older women, after adjusting by body mass index ([@bibr78-1559325815590395]).

Concluding Remarks {#section9-1559325815590395}
==================

The data reviewed earlier support the notion that the environmental estrogen, BPA, is involved in the metabolic programming of metabolic disorders such as obesity and T2DM. Exposure to low doses of BPA during critical periods of development has been shown to increase body weight (obesogenic action), alter glucose homeostasis (diabetogenic action), or both (diabesogenic action). In adult humans, epidemiological evidence also shows a positive relationship between BPA levels and the incidence of both diseases. More mechanistic insides are, nonetheless, required in order to completely understand the molecular basis of the obesogenic, diabetogenic, and diabesogenic actions of BPA.
